抗肿瘤药物相关间质性肺病诊治专家共识

Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease

药物引起的间质性肺病(DILD)是抗肿瘤药物临床应用中常见的肺部不良反应之一。近年来,随着临床肿瘤学的快速发展,大量新型抗肿瘤药物获得批准上市并广泛应用于临床,抗肿瘤药物相关间质性肺病的发病率也随之呈现逐年升高的趋势。DILD临床表现多样且缺乏特异性诊断标准,如果处理不当可导致治疗暂停或中断,甚至可危及患者生命。由中国临床肿瘤学、呼吸病学、影像学、药学、病理学和放疗领域的多位专家共同组成的抗肿瘤药物相关间质性肺病诊治专家共识专家委员会对抗肿瘤药物相关间质性肺病的诊治与管理进行多次研讨,最终达成抗肿瘤药物相关间质性肺病诊治专家共识。共识内容涵盖抗肿瘤药物相关间质性肺病的流行病学、发病机制、临床表现、诊断标准、治疗原则及多学科协作等多个方面,旨在提高临床医师对抗肿瘤药物相关间质性肺病的认识水平,规范临床诊治,倡导对肿瘤患者全方位、全周期的全程健康管理,从而改善患者预后及生活质量。

Drug-induced interstitial lung disease(DILD)is the most common pulmonary adverse events caused by anti-cancer treatment.In recent years,with the development of clinical oncology,a large amount of novel anti-cancer drugs have been approved and widely used in clinical practice,and the incidence of anti-cancer drug related DILD is gradually increasing.DILD lacks specific clinical manifestations or diagnostic criteria.If not treated properly,it may leads to interruption or discontinuation of anti-cancer treatment,or even become life threat in severe cases.Therefore,the Anti-cancer Drug-induced Interstitial Lung Disease Management Group have reached a consensus on the diagnosis and management of anti-cancer DILD after several rounds of discussion.This consensus aims to improve clinicians′awareness of anti-cancer drug related-DILD and proposes an algorithm for the diagnosis and treatment of this disease,and to improve patients′prognosis and quality of life.